China's Tot Biopharm starts work on second plant with eye on ADC market

By Gareth Macdonald

- Last updated on GMT


Related tags Biotechnology

Tot Biopharm has started work on a second monoclonal antibody (mAb) drug production plant at China’s Suzhou Industrial Park.

The plant will house five production lines with cell culture capacity of 2,000L and production capacity of 10,000L. Tot said it will use disposable bioreactor and processing systems.

The Chinese biopharmaceutical firm intends to use the facility to make antibody drug conjugates (ADC) for the local and international markets. It is scheduled to become operational in 2018 and to begin commercial production the following year.

Tot has been building up biopharmaceutical manufacturing capacity over the past few years beginning in 2012 when it opened its first production facility at the Suzhou site.

The existing facility houses an oral anti-cancer drug manufacturing area with separate production facilities for cytotoxics and non-cytotoxics, an injected anti-cancer drug plant and a GMP bio pilot plant with a capacity of 500L cell culture/ purification/ filling.


Work on the new facility follows just over six months after privately held Tot announced it had attracted what it called “new strategic shareholders.”

In March previous backer TTY Biopharm Co. had sold its Tot shareholding to a group including US investor Vivo Capital, Taiwan-based Formosa Laboratories – itself a producer of drug ingredients and ADCs – and Center Laboratories Group and Chengwei Capital.

At the time Tot said the transaction – valued at $24m (€21m) – would allow it to leverage Vivo’s experience in healthcare in both China and the US and facilitate strategic alliances including cross-border partnerships.

It also said closer financial ties with Formosa will bring benefits in bulk pharmaceutical chemical production and manufacturing.

Related news

Related products

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more